Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Discovering in vivo cytokine-eQTL interactions from a lupus clinical trial.

Davenport EE, Amariuta T, Gutierrez-Arcelus M, Slowikowski K, Westra HJ, Luo Y, Shen C, Rao DA, Zhang Y, Pearson S, von Schack D, Beebe JS, Bing N, John S, Vincent MS, Zhang B, Raychaudhuri S.

Genome Biol. 2018 Oct 19;19(1):168. doi: 10.1186/s13059-018-1560-8.

2.

Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.

Hua F, Comer GM, Stockert L, Jin B, Nowak J, Pleasic-Williams S, Wunderlich D, Cheng J, Beebe JS.

J Clin Pharmacol. 2014 Jan;54(1):14-22. doi: 10.1002/jcph.158. Epub 2013 Sep 17.

PMID:
23913720
3.

Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.

Arcari JT, Beebe JS, Berliner MA, Bernardo V, Boehm M, Borzillo GV, Clark T, Cohen BD, Connell RD, Frost HN, Gordon DA, Hungerford WM, Kakar SM, Kanter A, Keene NF, Knauth EA, Lagreca SD, Lu Y, Martinez-Alsina L, Marx MA, Morris J, Patel NC, Savage D, Soderstrom CI, Thompson C, Tkalcevic G, Tom NJ, Vajdos FF, Valentine JJ, Vincent PW, Wessel MD, Chen JM.

Bioorg Med Chem Lett. 2013 May 15;23(10):3059-63. doi: 10.1016/j.bmcl.2013.03.012. Epub 2013 Mar 21.

PMID:
23566514
4.

Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury.

Radi ZA, Koza-Taylor PH, Bell RR, Obert LA, Runnels HA, Beebe JS, Lawton MP, Sadis S.

Am J Pathol. 2011 Jul;179(1):240-7. doi: 10.1016/j.ajpath.2011.03.029. Epub 2011 May 13.

5.

PF-03475952: a potent and neutralizing fully human anti-CD44 antibody for therapeutic applications in inflammatory diseases.

Runnels HA, Weber GL, Min J, Kudlacz EM, Zobel JF, Donovan CB, Thiede MA, Zhang J, Alpert RB, Salafia MA, Milici AJ, Burdette D, Bell RR, Beebe JS, Xu X.

Adv Ther. 2010 Mar;27(3):168-80. doi: 10.1007/s12325-010-0010-0. Epub 2010 Apr 26.

PMID:
20429046
6.

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD.

Clin Cancer Res. 2005 Mar 1;11(5):2063-73.

7.

Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity.

Munchhof MJ, Beebe JS, Casavant JM, Cooper BA, Doty JL, Higdon RC, Hillerman SM, Soderstrom CI, Knauth EA, Marx MA, Rossi AM, Sobolov SB, Sun J.

Bioorg Med Chem Lett. 2004 Jan 5;14(1):21-4.

PMID:
14684289
8.

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG.

Cancer Res. 2003 Nov 1;63(21):7301-9.

9.

Microarray analysis uncovers retinoid targets in human bronchial epithelial cells.

Ma Y, Koza-Taylor PH, DiMattia DA, Hames L, Fu H, Dragnev KH, Turi T, Beebe JS, Freemantle SJ, Dmitrovsky E.

Oncogene. 2003 Jul 31;22(31):4924-32.

PMID:
12894236
10.

Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.

Lonardo F, Dragnev KH, Freemantle SJ, Ma Y, Memoli N, Sekula D, Knauth EA, Beebe JS, Dmitrovsky E.

Clin Cancer Res. 2002 Jan;8(1):54-60.

11.

3,5,3'-triiodothyronine (T3) receptor-auxiliary protein (TRAP) binds DNA and forms heterodimers with the T3 receptor.

Darling DS, Beebe JS, Burnside J, Winslow ER, Chin WW.

Mol Endocrinol. 1991 Jan;5(1):73-84.

PMID:
1850111
13.
14.

Combination of the chorionic gonadotropin free beta-subunit with alpha.

Beebe JS, Huth JR, Ruddon RW.

Endocrinology. 1990 Jan;126(1):384-91.

PMID:
1688410
15.

Identification and characterization of subpopulations of the free alpha-subunit that vary in their ability to combine with chorionic gonadotropin-beta.

Beebe JS, Krzesicki RF, Norton SE, Perini F, Peters BP, Ruddon RW.

Endocrinology. 1989 Apr;124(4):1613-24.

PMID:
2466636
16.

Conformational intermediates in the production of the combinable form of the beta-subunit of chorionic gonadotropin.

Ruddon RW, Krzesicki RF, Beebe JS, Loesel L, Perini F, Peters BP.

Endocrinology. 1989 Feb;124(2):862-9.

PMID:
2463905
17.

Detection of a glycosylated, incompletely folded form of chorionic gonadotropin beta subunit that is a precursor of hormone assembly in trophoblastic cells.

Ruddon RW, Krzesicki RF, Norton SE, Beebe JS, Peters BP, Perini F.

J Biol Chem. 1987 Sep 15;262(26):12533-40.

Supplemental Content

Loading ...
Support Center